Professional Summary

Professional Overview

Laura Veer is the Chief Research Officer at Agendia, a leading molecular diagnostics company, and a Professor of Laboratory Medicine as well as the Director of the Applied Genomics Cancer Center at the University of California, San Francisco (UCSF). With over 30 years of experience in the field of diagnostic oncology, she is a recognized expert in the application of advanced genomic technologies for cancer research and personalized medicine.

Experience Summary

Current Role

As the Chief Research Officer at Agendia, Laura is responsible for overseeing the company's research and development efforts, guiding the strategic direction of its innovative molecular diagnostic tests, and collaborating with industry partners and academic institutions to advance the field of precision oncology. In her role as Professor and Director at UCSF, she leads a multidisciplinary team of researchers focused on translating cutting-edge genomic insights into clinically actionable solutions for cancer patients.

Career Progression

Prior to her current positions, Laura held several notable roles, including Division Chair of Diagnostic Oncology at The Netherlands Cancer Institute and Chief Operating Officer at Agendia. She has a strong track record of driving organizational growth, fostering cross-functional collaboration, and spearheading the development of groundbreaking diagnostic tools that have significantly impacted the field of oncology.

Academic Background

Laura received her Ph.D. in Molecular Biology from Harvard Medical School, where she also completed a postdoctoral fellowship. She has maintained a strong academic presence throughout her career, contributing to numerous peer-reviewed publications and serving as a thought leader in her field.

Areas of Expertise

Laura's areas of expertise span a wide range of disciplines, including molecular genetics, cancer biology, bioinformatics, and translational research. She is a skilled leader, adept at aligning cross-functional teams, securing funding, and driving innovation in the rapidly evolving field of precision oncology.

Professional Impact

Under Laura's leadership, Agendia's flagship diagnostic tests have been adopted by healthcare providers worldwide, improving patient outcomes and transforming the way cancer is managed. Her research initiatives at UCSF have led to the development of novel biomarkers and personalized treatment strategies, making significant contributions to the understanding and treatment of various cancer types.

Conclusion

With her extensive expertise, entrepreneurial spirit, and commitment to advancing the field of diagnostic oncology, Laura Veer is poised to continue driving transformative change in the healthcare industry. Her unique blend of academic rigor, industry experience, and strategic vision make her a valuable asset in the pursuit of more effective and personalized cancer care.